Cidara Therapeutics, Inc.
CDTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $171 | $69 | $53 | $67 |
| - Cash | $190 | $36 | $33 | $62 |
| + Debt | $4 | $5 | $1 | $5 |
| Enterprise Value | -$16 | $39 | $21 | $9 |
| Revenue | $1 | $23 | $64 | $50 |
| % Growth | -94.5% | -63.9% | 30% | – |
| Gross Profit | $1 | -$13 | $64 | -$24 |
| % Margin | 100% | -57.9% | 100% | -47.4% |
| EBITDA | -$176 | -$27 | -$33 | -$42 |
| % Margin | -13,793.6% | -115.7% | -51.8% | -84.9% |
| Net Income | -$170 | -$23 | -$34 | -$42 |
| % Margin | -13,319.8% | -98.5% | -52.1% | -85.7% |
| EPS Diluted | -26.75 | -5.25 | -9.61 | -16.19 |
| % Growth | -409.5% | 45.4% | 40.6% | – |
| Operating Cash Flow | -$177 | -$22 | -$28 | -$25 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$177 | -$23 | -$29 | -$25 |